Apart from these, accelerated approval and breakthrough therapy designation (BTD) were granted, respectively, for Amivantamab and telisotuzumab vedotin for the treatment of c-Met-overexpressing non-small cell lung cancer (NSCLC) [18,19], signifying the importance of c-Met as a biomarker. The gene discussed is MET; the disease is non-small cell lung carcinoma.